Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02323100 · ClinicalTrials.gov registry record · Phase 1
Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)
A Phase 1 study, sponsored by National Jewish Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02323100 is a Phase 1 study that was terminated before completion, run by National Jewish Health. The registered enrollment target is 16 participants.
The verdict
NCT02323100, a Phase 1 study, was terminated before completion, sponsored by National Jewish Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
We propose to test the effectiveness of the combination of CF pancreatic enzyme replacement therapy (PERT) on absorption of Ravicti® and subsequent restoration of nasal epithelial cystic fibrosis transmembrane conductance regulator (CFTR)-mediated chloride transport during the nasal potential difference (NPD) test. Funding source FDA Office of Orphan Products Development.
Interventions
- DRUG Placebo
- DRUG Ravicti low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-12-02 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02323100
The ClinicalTrials.gov registry entry for NCT02323100 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02323100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02323100 about?
NCT02323100 is a clinical study titled "Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)". We propose to test the effectiveness of the combination of CF pancreatic enzyme replacement therapy (PERT) on absorption of Ravicti® and subsequent restoration of nasal epithelial cystic fibrosis transmembrane conductance regulator (CFTR)-mediated chloride transport during the nasal potential differ...
What is the current status of trial NCT02323100?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-12-02. Estimated completion is 2022-03-01.
What interventions are being tested in trial NCT02323100?
The interventions under investigation include: Placebo (DRUG), Ravicti low dose (DRUG).
Who is sponsoring clinical trial NCT02323100?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.